

Index

A

- Adult onset primary torsion dystonia (AOPTD), 37
- Age-related white matter changes (ARWMC), 63, 260
- Alzheimer's disease (AD), 20, 23, 111, 134
- γ -aminobutyric acid (GABA), 193
- Amyloid angiopathy, 261
- Anatomical connectivity, 29, 37
- Apparent diffusion coefficient (ADC), 12, 34, 188, 236
- Ataxia, 227
- Attenuation, 22, 49
- Atypical parkinsonism, 33–35, 67, 125, 133, 239
- Autosomal recessive ataxias
 - Ataxia telangiectasia (AT), 236
 - Friedreich's ataxia (FRDA), 236
- Autosomal recessive spastic ataxia of charlevoix–saguenay (ARSACS), 238

B

- B-value, 49, 55
- B1 heterogeneity, 160
- Basal ganglia (BG), 66, 275
- Bi-exponential decay, 54
- Bilateral striato-pallido-dentate calcinosis (BSPDC), 275–277, 281
- Biomarker, 32, 39, 79, 153, 166, 179, 205, 206, 211, 234, 239
- Blepharospasm (BLS), 35, 166, 168, 170, 172
- Blood oxygen level dependent (BOLD), 68, 143
- Blood oxygen level dependent functional MRI (BOLD-fMRI), 17, 19, 20, 191
- Bradykinesia, 67, 85, 105, 118, 119, 129, 131, 137, 187, 203, 205, 210, 281
- Brain neuroimaging, 79

Brain–computer interface (BCI) technology, 101

Brainstem raphe, 74, 75, 85, 86

C

- 12 β -carboxymethyl-3 β -(4-iodophenyl)-tropane (β -CIT), 235
- Cella media, 78
- Central nervous system (CNS), 1, 59, 165
- Cerebellar atrophy, 61, 122, 188, 214, 230, 232, 236
- Cerebellum, 66, 167
- Cerebral angiogram, 1
- Cerebral blood flow (CBF), 143
- Cerebral blood volume (CBV), 143
- Cerebral echomorphology, pathological changes, 73
- Cerebral vascular disease (CVD), 113
- Cervical dystonia (CD), 166, 171, 172
- Cervical myelopathy, 256
- Cervical spondylosis, 249, 256, 257
- Choreas, 201, 205, 207, 210, 214, 277, 281
- Chronic visual hallucinations, 148
- Collimators, 21
- Computational anatomy, 29, 32, 33, 35, 38, 40
- Computational neuroanatomy, 26, 27, 29, 41, 187
- Computed tomography (CT), 1, 71, 77, 201, 275
- Conventional MRI protocol
 - Echoplanar Imaging (EPI), 10
 - Fast Spin-Echo (FSE), 8
 - Gradient Recalled Echo (GRE), 9
 - Inversion recovery, 10
 - Spin-Echo (SE), 7
- Conventional radiologic principles, 2
- Corticobasal degeneration (CBD), 33, 83, 110
- Corticobasal syndrome (CBS), 105, 110, 162
- Creutzfeldt-Jakob's disease, 13, 121, 250

D

Data imaging, 27
 Deep brain stimulation (DBS), 30, 186
 Default mode network (DMN), 148, 152
 Dementia with Lewy bodies (DLB), 111
 Dentate nucleus (DN), 78
 18F-deoxy-glucose (FDG), 22, 60, 253, 281
 Dephasing, 5, 12
 Depression, 148
 Diffusion kurtosis, 54, 55
 Diffusion magnetic resonance imaging, 56
 Diffusion MRI, 51, 52
 Diffusion tensor imaging (DTI), 14, 26, 32, 50, 52–54, 167, 189, 207, 234, 261
 Diffusion-weighted imaging (DWI), 12, 26, 35, 38, 53, 188
 Dopamine dysregulation syndrome (DDS), 137
 Dopamine imaging, 134, 136, 138
 Dopamine transporter (DAT), 67, 130, 194
 Dopaminergic neuron loss, 29
 Dopaminergic neuronal loss, 52
 Doppler effect, 71
 Dynamic imaging of coherent sources (DICS), 195
 Dyslexia, 20
 Dystonia, 86
 pathogenesis, 35
 DYT1 dystonia, 165

E

Echo time (TE), 6
 Echo train length (ETL), 8
 Echoencephalography, 71
 Electroencephalography (EEG), 19, 101, 186
 Electromagnetism, 3, 4, 6
 Electromyography (EMG), 176, 186
 Electronic collimation, 22
 Electrophysiology, 168, 179
 Emission tomography, 12, 23
 Epidemiological studies, 30
 Essential tremor (ET), 39, 84, 186, 190, 192
 pathophysiology, 186
 treatment guidelines, 186
 Etiopathology, 40
 Excitation pulse, 4–7, 11

F

Fahr's disease, 275
 Fluid-Attenuated Inversion Recovery (FLAIR), 11
 Focal hand dystonia, 35, 36, 87, 165, 166, 174, 176
 Food and Drug Administration (FDA), 134

Fourier transformation, 7
 Fractional anisotropy (FA), 14, 26, 50, 125, 167, 261, 266
 Free induction decay (FID), 5
 Freezing of gait (FOG), 67, 253, 262, 277
 Functional connectivity, 146, 147, 149, 150, 152
 Functional magnetic resonance imaging (fMRI), 17, 19, 60, 68, 93, 99, 143, 144, 146, 147, 152, 153, 166, 170, 173, 176–178, 191, 207, 238
 Functional neuroimaging, 2, 19, 20, 23, 93, 95, 143, 187, 202
 Functional NIRS, 100, 102
 advantages, 94
 disadvantages, 95
 principle, 93

G

GABA receptor density, 211
 Gait
 abnormalities, 83
 activation, 59–61, 63, 66, 67
 activation study, 65
 apraxia, 255
 control, 247
 disorder, 67, 247–249, 261, 267
 disturbance, 67
 dysfunction, 67
 impairment, 30, 118, 256, 257, 259, 267
 improvement, 266
 movement, 66
 Gaussian Mixture Model and Principal Component Analysis (GMM/PCA), 28
 General linear model, 27
 Gilles de la Tourette syndrome, 40
 GLM analysis, 100
 Glucose
 hypermetabolism, 169
 metabolism, 169

H

Hallervorden-Spatz syndrome, 118
 Hemodynamics, 63
 High-field MRI, 17, 21, 123
 Huntington's disease (HD), 37, 112, 117, 201
 relaxometric studies, 39
 Hydrocephalus, 262
 Hyperechogenic ependyma, 77
 Hyperparathyroidism, 276
 Hypoechoogenicity, 73

I

- Idiopathic Parkinson disease, 52
- Idiopathic Parkinson disease (iPD), 29, 63, 72, 79, 105, 129, 144, 168, 185, 187, 235, 253, 277
 - hallmark, 29
- Inversion time (TI), 11
- Isochogenicity, 73, 77
- Isotropic Gaussian kernel, 27

K

- K-space, 7, 8, 10, 16

L

- Lewy body disorders, 134
- Locus ceruleus (LC), 159, 162, 163
- Longitudinal magnetization, 4
- Lymphoma, 22

M

- Magnetic resonance imaging (MRI), 2–7, 10, 17, 123, 159, 202, 227, 279, 280
 - neuroimaging method, 2
 - principles, 2
 - protocols, 7, 11
- Magnetic resonance spectroscopy (MRS), 14, 194, 208
- Magnetization transfer imaging (MTI), 206
- Magnetoencephalography (MEG), 186, 195
- Major depression, 85
- Mean diffusivity (MD), 50, 125, 169
- Meige syndrome, 87
 - 123I-MIBG scintigraphy, 80
- Microglial activation, 211
- Modern neuroscience, 1
- Montreal Neurological Institute (MNI), 65
- Morphometry, 25, 32, 34, 37, 38, 41
- Motor learning, 99, 144
- Motor sequence learning, 99
- Movement disorders, 26, 28, 33, 41, 54, 72, 78, 85–87, 93, 97, 102, 121, 123, 126, 165, 214, 277, 279
- MR parkinsonism index (MRPI), 110
- Multimodal imaging, 125
- Multiple regression analysis, 28
- Multiple sclerosis (MS), 119
- Multiple system atrophy (MSA), 34, 52, 53, 83, 105, 108, 133, 152, 162, 227, 239

N

- N-acetylaspartate (NAA), 234, 237
- NBIA (neurodegeneration with brain iron accumulation) syndrome, 112
- Near Infrared Spectroscopy (NIRS), 68, 93

- Network imbalance, 179
- Neuroacanthocytosis, 214
- Neurodegeneration with iron accumulation (NBIA), 118
- Neurodegenerative ataxias, evaluation, 234
- Neurodegenerative disorder, 108
- Neurofeedback system, 101
- Neuroimaging, 1, 2, 7, 8, 11, 12, 14, 17, 21–25, 32, 35, 59, 60, 68, 72, 95, 159, 165
 - history, 1
 - modalities, 94, 282
- Neurological disorder, 86, 114
- Neurological movement disorders, 52, 56
- Neuromelanin, 29, 81, 159, 160, 162
- Neuromelanin-sensitive images, 161–163
- Neuropathological studies, 32
- Nigrostriatal dopamine system, 81, 192, 195
- Non-motor symptoms, 85
- Normal pressure hydrocephalus (NPH), 83, 114
- Nuclear magnetic resonance (NMR) spectroscopy, 2

O

- Oculomotor apraxia, 236, 239
- Olivopontocerebellar atrophy (OPCA), 66
- Opportunistic infections, 120
- Organic aetiology, 134
- Orthostatic hypotension, 63, 240

P

- Paramagnetic agent, 106, 143, 160
- Parkin, 81
- Parkinson disease (PD), 23, 30, 56, 87, 97, 105, 136, 253, 281
- Parkinson disease (PD), 161, 210, 248, 279
- Parkinsonism, 32, 33, 117, 119, 123, 126, 132, 133, 214–217, 277, 281
- Pathophysiological changes, 81
- Phase-coherence, 4, 5
- Positron emission tomography (PET), 2, 21–23, 37, 59, 60, 66, 67, 80, 93–95, 99, 129–131, 135, 138, 143, 166, 167, 187, 192–194, 210–212, 216, 253, 266, 267, 280
- Postural control, 95–97, 99
- Postural imbalance, 152
- Precentral cortex, 167
- Precession, 4, 5
- Primary torsion dystonias (PTD),
 - pathophysiological mechanisms, 35
- Progressive supranuclear palsy (PSP), 33, 52, 53, 83, 105, 109
- Psychiatric symptoms, 238, 277
- Pursuit rotor (PR), 99

R

Radiofrequency (RF) pulse, 4
 Radiopharmaceuticals, 21–23
 Radiotracer, 59–61, 63, 64, 130, 152, 194, 210, 213
 Random-effects model, 100
 Receiver-operating characteristic (ROC), 55
 Recurrent sinopulmonary infections, 236
 Refocusing pulse, 7
 Region of interest (ROI), 27, 53, 258
 analysis, 189
 Relaxometry, 26
 REM sleep behavior disorder, 82
 Repetition time (TR), 6
 Repetitive transcranial magnetic stimulation (rTMS), 178, 192
 Resting state, 19, 149, 169
 Restless legs syndrome (RLS), 86
 Rotterdam progression scale, 260

S

Scans without evidence of dopaminergic deficit (SWEDDs), 133
 Schizophrenia, 20, 22, 163, 214
 Secondary intracerebral calcifications, 276
 Seed-points, 14
 Signal to noise ratio (SNR), 16, 123
 Single photon emission computed tomography (SPECT), 2, 19, 21–23, 59, 60, 80, 96, 135, 143, 187, 213, 280
 Single voxel proton magnetic resonance spectroscopy (1H-MRS), 172
 Single-voxel spectroscopy (SVS), 15
 Somatosensory system, 173
 Somatotopy, 40, 177
 Spasmodic dysphonia (SD), 166, 173
 Spastic paraparesis, 256
 Speech control system, 174
 Spin-lattice relaxation, 5
 Spinocerebellar ataxia (SCA), 79, 97, 108, 228, 280
 Standing posture, 66, 67, 93–96
 Static magnetic field, 3
 Striatal dopamine deficiency, 105
 Structural imaging, 12, 40, 105, 113, 119, 126, 161, 168

Structural MRI, 22, 41, 95, 106, 108, 117
 Subcortical arteriosclerotic encephalopathy (SAE), 261
 Subcortical hemispheric disease, 253
 Substantia nigra (SN), 53, 55, 72, 74, 79, 105
 Substantia nigra hyperechogenicity, 87
 causes, 81
 Substantia nigra pars compacta (SNc), 159
 Supplementary motor area (SMA), 65, 167, 177, 190
 Support-vector machines (SVMs), 28

T

T2 relaxation, 5
 Thalamic astasia, 251
 Tissue harmonic imaging (THI), 73
 Tourette's Syndrome, 214
 Toxic-induced parkinsonism, 116
 Tract-based spatial statistics (TBSS), 39, 52, 189, 234
 Tractography, 14, 37, 52, 166, 172, 190
 Transcranial sonography (TCS), 195, 217, 279
 Transcranial ultrasound (TCS), *See* Transcranial sonography (TCS), 71

U

Ultrasonography, 213
 Unified Huntington's Disease Rating Scale (UHDRS), 203
 Unified Parkinson's Disease Rating Scale (UPDRS), 54, 131, 149

V

Vascular brain disease, 257
 Vascular parkinsonism (vPD), 63, 67, 113, 134
 Voxel(s) of interest (VOI), 15
 Voxel-based morphometry (VBM), 27, 30–34, 108, 174, 188, 202, 231, 239, 258
 Voxel-based quantification (VBQ), 34
 Voxel-based relaxometry (VBR), 109
 Voxels for all connectivity-defined sub-regions (VCDR), 125

W

White matter disease, 206, 216, 259, 261
 Wilson's disease, 85, 112, 118, 214, 216, 280